Form 4: uniQure CLO Jeannette Potts Reports Equity Grants

uniQure N.V.'s Chief Legal Officer, Jeannette Potts, reported the acquisition of restricted share units and stock options, alongside a tax-related sale of shares.

Summary

• Chief Legal Officer Jeannette Potts was granted 35,400 restricted share units (RSUs) of uniQure N.V. Ordinary Shares on March 4, 2026.
• These RSUs represent the contingent right to receive one Ordinary Share each and will vest in three equal annual installments, beginning on the first anniversary of the grant date.
• Potts also received 57,200 stock options with an exercise price of $9.04, which will vest 25% on the first anniversary of the grant date and 6.25% quarterly thereafter until fully vested.
• A sale of 3,412 Ordinary Shares occurred at a weighted average price of $9.06, solely to cover estimated withholding taxes upon the vesting of restricted share units.
• This sale was executed pursuant to automatic sale instructions under a Rule 10b5-1(c) plan and was not a discretionary trade by the reporting person.
• Following these transactions, Potts beneficially owns 138,483 Ordinary Shares and 57,200 stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting standard executive compensation practices that align management incentives with company performance, with the tax-related sale being non-discretionary.

Positives

• The grant of 35,400 restricted share units and 57,200 stock options aligns management's long-term interests with shareholder value.
• The transactions were made pursuant to a Rule 10b5-1(c) plan, indicating pre-planned equity compensation and reducing concerns about opportunistic trading.

Negatives

• A sale of 3,412 Ordinary Shares occurred, reducing direct beneficial ownership, although it was for tax purposes and not a discretionary trade.

Future Outlook

The reporting person's future equity ownership is tied to vesting schedules for restricted share units and stock options, which will occur over several years, subject to continued employment with uniQure N.V.

Management Comments

• The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement.
• The sale was not a discretionary trade by the Reporting Person.

Industry Context

StockSavvy.ai notes that equity grants to executive officers like Chief Legal Officers are standard practice in the biotechnology and pharmaceutical industries, aiming to incentivize long-term performance and align management interests with shareholder returns. The use of a 10b5-1 plan for tax-related sales is also a common and transparent mechanism.

Stakeholder Impact

• Shareholders: The grants align management's long-term interests with shareholder value. The tax-related sale is a minor, non-discretionary event. Potential future dilution from option exercise.
• Employees: Reflects standard executive compensation practices.

Next Steps

• Vesting of 1/3 of the 35,400 Restricted Share Units annually, starting March 4, 2027.
• Vesting of 25% of the 57,200 Stock Options on March 4, 2027, followed by quarterly vesting of 6.25% thereafter.

Key Dates

Keywords

uniQure, QURE, Jeannette Potts, Chief Legal Officer, Insider Transaction, Form 4, Restricted Share Units, Stock Options, Equity Compensation, SEC Filing